After a series of marketing meetings with management, Paradigm Capital analyst Daniel Rosenberg has maintained his “Buy” rating on Converge Technology Solutions (Converge Technology Solutions Stock Quote, Chart, News, Analysts, Financials TSX:CTS).
“Yesterday, we hosted marketing meetings with Greg Berard, CEO, and Avjit Kamboj, CFO,” the analyst wrote. “The meetings highlighted Converge’s operational updates, capital allocation priorities and longer-term targets. The outlook was positive as leadership continues to see growth in its high-value service areas growing in the double digits. CTS’ end-to-end platform, which offers both “breadth and depth” and is emerging as a key point of differentiation. The company is focused on hiring new sales, as well as exploring nearshoring/offshoring capabilities as it enters its next stage of growth. Internal integration work and a new ERP system are also driving greater efficiencies and supporting profitability. We have seen CTS mature from a small-cap VAR roll-up to a leading provider of IT solutions. With the company expanding margins and growing FCF, we believe shares offer significant value.”
In a research update to clients September 25, Rosenberg maintained his “Buy” rating and price target of $7.25 on CTS, implying a return of 65.5% at the time of publication.
Rosenberg thinks CTS will post Adjusted EBITDA of $182.4-million on revenue of $2.64-billion in fiscal 2024. He expects those numbers will improve to Adjusted EBITDA of $199.9-million on revenue of $2.77-billion in fiscal 2025.
“We have made minor adjustments to our forecast following the meetings. We utilize a blend of DCF and EBITDA multiple to derive our target price. For our DCF, we use a WACC of 10.00% and a 2% terminal growth rate. We use an 8.0x multiple on our 2025e EBITDA, which results in our blended target price of $7.25. Converge trades at 5.7x 2025e adjusted EBITDA versus peers at 7.2x. We continue to believe higher cash flow generation will continue to drive share performance,” the analyst added.
Haywood Securities analyst Neal Gilmer says lower Canadian cannabis market share is weighing on Tilray Brands (Tilray Brands Stock Quote,… [Read More]
National Bank Financial analyst Baltej Sidhu says Anaergia’s (Anaergia Stock Quote, Chart, News, Analysts, Financials TSX:ANRG) divestiture of two legacy… [Read More]
RBC assistant chief economist Cynthia Leach says the public sector is playing a larger role in Canada’s investment boom than… [Read More]
Research Capital analyst Andre Uddin says Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials TSX:EPRX) reported another strong… [Read More]
Roth Capital Partners analyst Craig Irwin says VersaBank (VersaBank Stock Quote, Chart, News, Analysts, Financials NASDAQ:VBNK) is nearing a potential… [Read More]
Roth Capital Partners analyst Max Masucci says Rapid Micro Biosystems (Rapid Micro Biosystems Stock Quote, Chart, News, Analysts, Financials NASDAQ:RPID)… [Read More]